What question did this study set out to answer?

To compare clinical outcomes in critically ill trauma patients treated with either ampicillin-sulbactam or imipenem-cilastatin for Acinetobacter ventilator-associated pneumonia.

June 1, 2002Clinical Infectious DiseasesOpen Access

Comparison of Ampicillin‐Sulbactam and Imipenem‐Cilastatin for the Treatment ofAcinetobacterVentilator‐Associated Pneumonia

View Full Paper

Ask AI

Bookmark

Authors

GWG. Christopher WoodUniversity of Tennessee Health Science Center SHScott D. HanesRosalind Franklin University of Medicine and Science MCMartin A. CroceUniversity of Tennessee Health Science Center

Discussion

Member takes

Implication

Retrospective study finds similar efficacy between ampicillin-sulbactam and imipenem-cilastatin in Acinetobacter ventilator-associated pneumonia, suggesting sulbactam is a viable alternative.

Key Points

To compare clinical outcomes in critically ill trauma patients treated with either ampicillin-sulbactam or imipenem-cilastatin for Acinetobacter ventilator-associated pneumonia.
Retrospective comparative analysis of 77 episodes of Acinetobacter ventilator-associated pneumonia across 75 critically ill trauma patients.
Treatment arms evaluated were ampicillin-sulbactam (n=14) and imipenem-cilastatin (n=63), with documented use of adjunctive aminoglycoside therapy.
Treatment efficacy reached 93% in the ampicillin-sulbactam group compared to 83% in the imipenem-cilastatin group (P > .05).
No statistically significant differences occurred between groups regarding associated mortality, mechanical ventilation duration, or intensive care unit and hospital lengths of stay.
Adjunctive aminoglycosides were administered more frequently in the ampicillin-sulbactam cohort, primarily because of baseline imipenem resistance.

Cite This Study

Wood et al. (2002) studied this question.

synapsesocial.com/papers/6a7d397c2f2f9d79738b26f3 https://doi.org/10.1086/340055

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study finds similar efficacy between ampicillin-sulbactam and imipenem-cilastatin in Acinetobacter ventilator-associated pneumonia, suggesting sulbactam is a viable alternative.

Comparison of Ampicillin‐Sulbactam and Imipenem‐Cilastatin for the Treatment ofAcinetobacterVentilator‐Associated Pneumonia

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparison of Ampicillin‐Sulbactam and Imipenem‐Cilastatin for the Treatment ofAcinetobacterVentilator‐Associated Pneumonia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider